|Positive FC detected in||mouse splenocytes|
|This reagent has been tested for flow cytometric analysis. It is recommended that this reagent should be titrated in each testing system to obtain optimal results.|
|Sample-dependent, check data in validation data gallery|
PE-65069 targets CD8a in FC applications and shows reactivity with Mouse samples.
|Host / Isotype||Rat / IgG2a, kappa|
|Immunogen||Spleen cells or thymocyte membranes|
|Full Name||CD8 antigen, alpha chain|
|GenBank accession number||BC030679|
|Gene ID (NCBI)||12525|
|Conjugate||PE Fluorescent Dye|
|Excitation/Emission maxima wavelengths||496 nm, 565 nm / 578 nm|
|Purification Method||Affinity purification|
|Storage Buffer||PBS with 0.09% sodium azide and 0.5% BSA.|
|Storage Conditions||Store at 2-8°C. Avoid exposure to light. Stable for one year after shipment.|
CD8 is a transmembrane glycoprotein composed of two disulfide-linked chains. It can be present as a homodimer of CD8α or as a heterodimer of CD8α and CD8β (PMID: 3264320; 8253791). CD8 is found on most thymocytes. The majority of class I-restricted T cells express mostly the CD8αβ heterodimer while CD8αα homodimers alone have been found on some gut intraepithelial T cells , on some T cell receptor (TCR) γδ T cells and on NK cells (PMID: 2111591; 1831127; 8420975). CD8 acts as a co-receptor that binds to MHC class-I and participates in cytotoxic T cell activation (PMID: 8499079). During T cell development, CD8 is required for positive selection of CD4-/CD8+ T cells (PMID: 1968084).
Tailor-Made Autophagy Cascade Amplification Polymeric Nanoparticles for Enhanced Tumor Immunotherapy
Multi-material basis and multi-mechanisms of the Dahuang Zhechong pill for regulating Treg/Th1 balance in hepatocellular carcinoma.
J Mater Chem B
PD-1 engineered cytomembrane cloaked molybdenum nitride for synergistic photothermal and enhanced immunotherapy of breast cancer
Asian J Pharm Sci
Lignin-assisted construction of sub-10 nm supramolecular self-assembly for photothermal immunotherapy and potentiating anti-PD-1 therapy against primary and distant breast tumors